Lumira Ventures

About The Fund

Lumira Ventures is a venture capital firm specializing in the healthcare sector, with a focus on investments within life sciences, biotechnology, medical technologies, digital health, and consumer healthcare. Founded in 1998 and headquartered in Toronto, Canada, Lumira Ventures aims to empower visionary entrepreneurs to drive transformational innovation within the healthcare industry. They are committed to proactive care with a heartfelt impact, seeking to support the advancement of medical technologies and therapies that provide more accurate solutions for life-saving care. Lumira Ventures takes pride in their significant contributions to healthcare, highlighting their portfolio's success in tackling over 40 diseases, gaining 35+ approved products, accumulating over $75 billion in cumulative revenue from these products, and treating more than 5 million patients. Their investments are also substantial in their ability to raise capital for portfolio companies, boasting over $6 billion raised. With a clear investment thesis that prioritizes disruptive and innovative therapies, Lumira Ventures has an extensive impact on fields such as heart failure management, women’s cardiovascular health, cancer therapies, and robotic surgery, amongst others. Their focus on companies that can lead to reduced need for kidney transplants, on-demand termination of epileptic seizures, and the cure for chronic diseases like Hepatitis C, demonstrate their dedicated approach to improving quality of life and care. Lumira Ventures operates across multiple locations, including their headquarters in Toronto and offices in Montreal, Vancouver, and Boston, indicating a geographically diverse investment approach. They are also clear on their performance metrics, stating that their success is not only measured by returns to their investors but also by the impact their investments make in the healthcare ecosystem. Their minimum and maximum fund investment values indicate a strategic focus on seed-stage investments.